ovid.com
Cure8 news brief
Why This Matters
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or other signs of nephrotic syndrome while on therapy.
Although uncommon, recognizing potential drug‑related kidney problems early can allow prompt evaluation and management, including consideration of stopping the drug.
Who Should Pay Attention
Adults with Crohn’s disease on ustekinumab or other biologics; clinicians who prescribe or monitor biologic therapy (gastroenterologists, nephrologists); patients experiencing new edema, heavy proteinuria, or signs of kidney dysfunction.
Study Snapshot
Story typeResearch paper
Evidence typeCase report
Source depthFull source text
What To Know
A 22‑year‑old woman with Crohn’s disease developed nephrotic‑range proteinuria and was diagnosed by renal biopsy with focal segmental glomerulosclerosis (FSGS) after escalation of ustekinumab. Stopping ustekinumab was followed by resolution of symptoms and proteinuria, and the authors report this as a case of secondary FSGS potentially linked to ustekinumab.
The report describes the patient’s IBD history (prior azathioprine, adalimumab, infliximab, surgery) and the timeline of ustekinumab escalation before the onset of edema and heavy proteinuria. Renal biopsy findings consistent with FSGS are presented, and common alternative causes were investigated and reportedly negative.
The article frames this as a possible drug‑related adverse event and emphasizes renal monitoring in patients on biologics. This is a single case report; it cannot establish causation but raises a safety signal clinicians and patients on ustekinumab may wish to be aware of. Further study and pharmacovigilance data would be needed to assess risk.
Keep In Mind
This is a single case report published in a medical journal. Case reports can highlight possible adverse events but do not prove a cause‑and‑effect relationship. The authors report the patient improved after stopping ustekinumab, but larger studies or pharmacovigilance analyses would be needed to confirm a true association.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationovid.com
Indexed viaGoogle News
Source typeWeb article
PublishedAug 11, 2026, 4:35 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...